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Aims Although the nature of the humoral factor which mediates cardioprotection established by remote ischaemic condi-
tioning (RIc) remains unknown, parasympathetic (vagal) mechanisms appear to play a critical role. As the produc-
tion and release of many gut hormones is modulated by the vagus nerve, here we tested the hypothesis that RIc
cardioprotection is mediated by the actions of glucagon-like peptide-1 (GLP-1).
....................................................................................................................................................................................................
Methods
and results
A rat model of myocardial infarction (coronary artery occlusion followed by reperfusion) was used. Remote ischae-
mic pre- (RIPre) or perconditioning (RIPer) was induced by 15min occlusion of femoral arteries applied prior to or
during the myocardial ischaemia. The degree of RIPre and RIPer cardioprotection was determined in conditions of
cervical or subdiaphragmatic vagotomy, or following blockade of GLP-1 receptors (GLP-1R) using specific antago-
nist Exendin(9–39). Phosphorylation of PI3K/AKT and STAT3 was assessed. RIPre and RIPer reduced infarct size by
50%. In conditions of bilateral cervical or subdiaphragmatic vagotomy RIPer failed to establish cardioprotection.
GLP-1R blockade abolished cardioprotection induced by either RIPre or RIPer. Exendin(9–39) also prevented
RIPre-induced AKT phosphorylation. Cardioprotection induced by GLP-1R agonist Exendin-4 was preserved fol-
lowing cervical vagotomy, but was abolished in conditions of M3 muscarinic receptor blockade.
....................................................................................................................................................................................................
Conclusions These data strongly suggest that GLP-1 functions as a humoral factor of remote ischaemic conditioning cardioprotection.
This phenomenon requires intact vagal innervation of the visceral organs and recruitment of GLP-1R-mediated signalling.
Cardioprotection induced by GLP-1R activation is mediated by a mechanism involving M3 muscarinic receptors.
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1. Introduction
Powerful innate mechanisms of cardioprotection can be recruited by
remote ischaemic conditioning (RIc), which can be established by cycles
of ischaemia/reperfusion applied to an organ/tissue distant from the
heart. In several animal models significant reduction of myocardial
ischaemia/reperfusion injury was demonstrated when RIc stimulus was
applied either before (remote ischaemic preconditioning, RIPre) or dur-
ing myocardial ischaemia (remote ischaemic perconditioning, RIPer),1,2
or after the onset of reperfusion (remote ischaemic postconditioning).3
Clinical trials have demonstrated the efficacy of RIc in reducing infarct
size in patients with an acute myocardial infarction (AMI),4,5 in reducing
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myocardial damage during cardiac surgery6 and improving long term
prognosis in both patient cohorts.6,7 Although the exact mechanisms
underlying RIc cardioprotection are not fully understood, a number of
studies suggested the involvement of both humoral8–11 and neural signal-
ling pathways.1,12–14 Several candidate humoral factors of RIc have been
proposed, including stromal cell-derived factor-1a,15 nitrite/nitric
oxide,16 interleukin-10,17 microRNA-144,18 apolipoprotein A-I19 and
alpha-ketoglutarate-dependent dioxygenase Egln1.20 However, the full
extent of RIc cardioprotection cannot be explained by the actions of any
of these factors alone.
There is strong evidence that parasympathetic (vagal) mechanisms are
critically important for RIPre cardioprotection. RIPre was reported to be
abolished by selective genetic inhibition of brainstem vagal preganglionic
neurones,13 muscarinic receptor blockade,13,14 bilateral cervical vagot-
omy3 or sectioning of the posterior gastric branch of the vagus nerve.21
Electrical stimulation of the whole vagus nerve at the cervical level22,23
or isolated posterior gastric branch of the vagus21 establishes cardiopro-
tection. These data suggest that visceral organs, innervated by the poste-
rior gastric branch of the vagus nerve, are the likely source of a humoral
factor (or factors) of RIc cardioprotection. Glucagon-like peptide-1
(GLP-1) is the most notable of all humoral factors, which originate from
the visceral organs and known to have cardioprotective properties.
GLP-1 is an incretin hormone released by the L-cells of the intestine in
response to the ingestion of food.24,25 Release of GLP-1 is modulated by
vagal efferent (motor) activity26,27 and there is also evidence that GLP-1
may interact with vagal sensory fibres innervating the viscera.26 GLP-1
actions appear to be mediated via glucagon-like peptide-1 receptor
(GLP-1R)-dependent and independent mechanisms,28,29 although the
existence of the latter is debated. Studies conducted in animal models
demonstrated potent cardioprotection by GLP-1R activation.30 The effi-
cacy of GLP-1R agonists in reducing infarct size was also shown in human
studies.31,32 Recent study conducted in patients with type 2 diabetes
demonstrated significant reduction in frequency of adverse cardiovascu-
lar events and death from cardiovascular causes by treatment with GLP-
1 analogue liraglutide.33 The molecular weight of GLP-1 is3.3 kDa and
it appears to satisfy the key criteria of the humoral preconditioning factor
(including molecular weight of less than 8 kDa), suggested by Lang and
colleagues on the basis of the proteomic analysis of blood samples
obtained from experimental animals receiving the RIPre stimulus.34
This study was designed to test the hypothesis that cardioprotection
established by RIc is mediated by the actions of GLP-1. Taken into the
account that the parasympathetic nervous system appears to be critically
important for RIPre cardioprotection, we also investigated the signifi-
cance of vagal mechanisms in establishing cardioprotection induced by
the GLP-1R agonist Exendin-4 (Ex4).
2. Methods
All the experiments were performed in accordance with the European
Commission Directive 2010/63/EU (European Convention for the
Protection of Vertebrate Animals used for Experimental and Other
Scientific Purposes) and the UKHomeOffice (Scientific Procedures) Act
(1986) with project approval from the respective Institutional Animal
Care and Use Committees.
2.1 Animal preparation
Adult male Sprague Dawley rats (280–320 g) were anaesthetized with
pentobarbital sodium (induction 60mg kg1 i.p.; maintenance 15mg
kg1 h1 i.v.). Adequate anaesthesia was ensured by maintaining stable
levels of the arterial blood pressure and heart rate and confirmed by the
absence of a withdrawal response to a paw pinch. The right carotid
artery and left jugular vein were cannulated for the measurement of the
arterial blood pressure and administration of anaesthetic or test com-
pounds, respectively. The trachea was cannulated to allow mechanical
ventilation with room air using a positive pressure rodent ventilator
(tidal volume 8–10ml kg1; frequency 60 strokes min1). Partial
pressures of O2 and CO2 as well as pH of the arterial blood were meas-
ured regularly. A standard lead II ECGwas recorded. The body tempera-
ture was maintained at 37.06 0.5 C with a servo-controlled heating
blanket.
2.2 Model of myocardial infarction
An established rat model of myocardial ischaemia/reperfusion injury was
used.3,13,21 The heart was exposed via a left thoracotomy and a 5–0
monofilament polypropylene suture was passed around the left anterior
descending coronary (LAD) artery to induce a temporary occlusion.
LAD artery was occluded for 30min followed by reperfusion lasting
120min.
2.3 Infarct size measurement
At the end of the reperfusion period, the LAD artery was ligated, and 5%
Evans Blue dye solution (0.2ml) was infused via the jugular vein to deter-
mine the area at risk. The animal was then given an anaesthetic overdose
(pentobarbital, 200mg kg1, i.v.), the heart was excised, the left ventricle
(LV) was isolated, frozen, and sectioned into 5–6 transverse slices from
the apex to the base. The area at risk was demarcated by the absence of
Evans Blue staining. LV slices were then incubated with 1% 2,3,5-triphe-
nyltetrazolium chloride (TTC) in Tris buffer (pH 7.4) for 15min at 37 C
and fixed in 4% formalin for 24 h. Viable myocardium is stained red by
TTC, whereas necrotic myocardium appears white. The area at risk and
the necrotic area were determined by computerized planimetry, nor-
malized to the weight of each slice, with the degree of necrosis (i.e.
infarct size) expressed as the percentage of area at risk, as
described.3,13,21
2.4 Immunoblotting
For the analysis of protein phosphorylation, Western blot was per-
formed on the myocardium from the area at risk. The ventricular tissue
was excised, frozen in liquid nitrogen and stored at 80 C before
the assays. Total phosphatidylinositol 3-kinase AKT (PI3K/AKT),
phospho-AKT (Ser473), janus-activated kinase (JAK) signal transducer
and activator of transcription (STAT3) and phospho-STAT3 (Tyr705)
were immunodetected in cell lysates (whole cell fractions) using specific
primary antibodies (all from Cell Signalling Technology, UK). Proteins
were electrophoretically separated in SDS-PAGE gels and transferred to
polyvinylidene difluoride membranes (Amersham Biosciences, USA)
according to the manufacturer’s instructions. After antibody labelling,
detection was performed (ECL detection system, Amersham
Biosciences, USA). Densitometry was used to calculate the ratio
of phosphorylated and total protein normalized to the expression of
b-actin (Santa Cruz UK) to control protein loading.
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2.5 Experimental protocols
2.5.1 Experiment 1. The effect of vagotomy on RIPer
cardioprotection
There is evidence that RIPre cardioprotection is abolished in conditions
of either cervical3 or subdiaphragmatic21 vagotomy. However, the role
of parasympathetic mechanisms in mediating RIPer cardioprotection
remains unknown. RIPer was induced by occlusion of both femoral
arteries for 15min starting 10min after the onset of myocardial ischae-
mia (see timeline Figure 1A). For bilateral cervical vagotomy, both nerves
were exposed at the neck level and sectioned 15min prior to myocardial
ischaemia. To perform total subdiaphragmatic vagotomy, minimal inci-
sion was made to gain access to the abdominal cavity, the left lobes of
the liver were gently pulled aside, the stomach was retracted caudally to
expose the oesophagus, the vagal trunks were carefully dissected under
the diaphragm and sectioned.21,35
2.5.2 Experiment 2. The effect of GLP-1 receptor blockade
on RIc-induced cardioprotection and phosphorylation of
AKT and STAT3
RIc was induced by 15min occlusion of both femoral arteries, followed
by reperfusion, starting either 25min prior or 10min after the onset of
myocardial ischaemia (see timeline Figure 2A). GLP-1R antagonist
Exendin(9–39) (Ex(9–39), 50 mg kg1, i.v.),36,37 was administered 40min
or 15min before the onset of ischaemia in animals receiving the RIPre or
RIPer stimulus, respectively. The effect of Ex(9–39) on cardioprotection
established by classical myocardial ischaemic preconditioning (IPre) was
also determined. IPre was induced by three episodes of myocardial
ischaemia (LAD occlusion; 3þ 5þ 5min) separated by 5-min periods of
reperfusion. Ex(9–39) was given 15min before the first ischaemic epi-
sode. The dose of Ex(9–39) was selected on the basis of previously pub-
lished reports.38 In a separate experiment the effect of Ex(9–39) on
RIPre-induced phosphorylation of AKT and STAT3 in the myocardium
was assessed. The hearts were collected 15min after the onset of myo-
cardial reperfusion.
2.5.3 Experiment 3. The effect of vagotomy and systemic
muscarinic receptor blockade on cardioprotection
established by GLP-1 receptor activation
Intravenous administration of GLP-1R agonist Exendin-4 (Ex4) in doses
ranging between 1–10lg kg1 has been shown to protect the rat heart
against myocardial ischaemia/reperfusion injury.39 In this study we used
Ex4 in 5lg kg1 dose to determine the efficacy of GLP-1R activation in
establishing cardioprotection in conditions of bilateral cervical vagotomy,
systemic muscarinic receptor blockade (atropine methyl nitrate; initial
bolus dose 2mg kg1, i.v., followed by infusion at a rate of 1mg kg1 h1)
or M3 muscarinic receptor blockade (4-DAMP; 2mg kg1, i.v).
Experimental protocols are illustrated on Figure 3A.
2.5.4 Experiment 4. The effect of RIc on plasma level of
GLP-1
After 12-h overnight fast, the animals were anaesthetized and instru-
mented as described above. RIc was induced by 15min occlusion of both
femoral arteries, followed by reperfusion. Samples of the arterial blood
(300 ml) were collected into pre-chilled EDTA-Eppendorf tubes at 4
time points: 10min prior to and 5, 20, and 30min after the onset of limb
ischaemia or sham-RIc. Dipeptidyl peptidase-4 (DPP-4) inhibitor (50 mM;
EMDMillipore) was added to the collected samples and plasma was sep-
arated by centrifugation (10min; 1000 g; 4C). Total GLP-1 in plasma
was measured using MesoScale Discovery Total GLP-1 (v2) kit
(Rockville, USA).
Figure 1 Cardioprotection induced by remote ischaemic percondi-
tioning requires intact parasympathetic innervation of visceral organs.
(A) Illustration of the experimental protocols. In all the protocols, the
rat model of myocardial infarction involved 30min of left anterior
descending coronary artery occlusion followed by 120min of reperfu-
sion. Arrows indicate time (15min before myocardial ischaemia) of
bilateral cervical (cerv.) or subdiaphragmatic (subd.) vagotomy. Remote
ischaemic perconditioning (RIPer) was induced by occlusion of both
femoral arteries for 15min starting 10min after the onset of myocardial
ischaemia. (B) Infarct size is presented as a percentage of the area at
risk. Individual data and means6 SD are shown. **P< 0.01;
***P< 0.001.
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2.6 Statistical analysis
One-way ANOVA (Tukey’s and Bonferroni’s Multiple Comparison
Tests) was used for statistical analysis of the data. Values of P< 0.05
were considered to be significant.
3. Results
In the Experiment 1, an increase in heart rate was observed in animals
subjected to RIPer in conditions of subdiaphragmatic vagotomy during
myocardial ischaemia and reperfusion period (Supplementary material
online, Table). In the Experiment 3, mean arterial blood pressure
increased in Ex4-treated animals subjected to cervical vagotomy before
myocardial ischaemia. Heart rate increased before myocardial ischaemia
and remained elevated during myocardial ischaemia and during reperfu-
sion (Supplementary material online, Table). No other differences in
mean arterial blood pressure and heart rate during ischaemia and reper-
fusion were observed between the experimental groups of animals
(Supplementary material online, Table). Areas at risk were similar
between all the experimental groups (data not shown). Figures 1B, 2B,
Figure 2 GLP-1 receptors mediate remote ischaemic conditioning cardioprotection. (A) Illustration of the experimental protocols. Myocardial ischae-
mic preconditioning (IPre) was induced by three episodes of myocardial ischaemia (3þ 5þ 5min) separated by 5-min periods of reperfusion. Remote
ischaemic preconditioning (RIPre) was induced by occlusion of both femoral arteries for 15min starting 25min before the onset of myocardial ischaemia.
Arrows indicate the time (15min before IPre, RIPre or myocardial ischaemia) of intravenous administration of GLP-1 receptor antagonist Exendin(9–39)
(Ex(9–39)). (B) Infarct size is presented as a percentage of the area at risk. Individual data and means6 SD are shown. **P< 0.01; ***P< 0.001. (C) Left:
representative immunoblots showing total AKT and phospho-AKT (Ser473) protein expression in left ventricular lysates at 15min of myocardial reperfu-
sion in rats subjected to preparative sham surgery (sham-RIPre), application of RIPre stimulus, or application of RIPre stimulus in conditions of systemic
GLP-1R blockade with Ex(9–39). Right: summary data illustrating means6 SD of the densitometry of phospho-AKT-to-AKT ratio. *P< 0.05. (D) Left: rep-
resentative immunoblots showing total STAT3 and phospho-STAT3 (Tyr705) protein expression in left ventricular lysates at 15min of myocardial reper-
fusion in rats subjected to preparative sham surgery (sham-RIPre), application of RIPre stimulus, or application of RIPre stimulus in conditions of systemic
GLP-1R blockade with Ex(9–39). Right: summary data illustrating means6 SD of the densitometry of phospho-STAT3-to-STAT3 ratio.
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and 3B illustrate infarct sizes expressed as percentages of the areas at
risk.
3.1 Experiment 1. The effect of vagotomy
on RIPer cardioprotection
Average infarct size in animals subjected to 30min of LAD occlusion fol-
lowed by 120min of reperfusion was 566 10% (Figure 1B). RIPer signifi-
cantly reduced myocardial ischaemia/reperfusion injury (infarct size
276 6%, P< 0.001), but failed to establish cardioprotection in condi-
tions of either bilateral cervical or subdiaphragmatic vagotomy (Figure
1B). Vagotomy per se had no effect on myocardial ischaemia/reperfusion
injury (Figure 1B).
3.2 Experiment 2. The effect of GLP-1
receptor blockade on RIc-induced
cardioprotection and phosphorylation of
AKTand STAT3
To determine whether GLP-1 may act as a humoral factor of RIc we
next determined the efficacy of IPre, RIPre, and RIPer in establishing car-
dioprotection in conditions of systemic GLP-1R blockade (Figure 2B).
Systemic administration of a specific GLP-1R antagonist Ex(9–39)
blocked cardioprotection induced by RIPre and RIPer (infarct sizes
486 10% and 526 9%, respectively), but had no effect on cardioprotec-
tion conferred by classical direct myocardial IPre (infarct size 246 4%)
(Figure 2B). RIPre-induced AKT phosphorylation was blocked (P< 0.05)
by systemic treatment with Ex(9–39) (Figure 2C). RIPre had no significant
effect on STAT3 phosphorylation (Figure 2D).
3.3 Experiment 3. The effect of vagotomy
and systemic muscarinic receptor blockade
on cardioprotection established by GLP-1
receptor activation
We next determined whether GLP-1R activation induces cardiopro-
tection via recruitment of vagal mechanisms. Intravenous infusion of
GLP-1R agonist Ex4 significantly reduced (by 40%, P< 0.01) the
extent of myocardial ischaemia/reperfusion injury (Figure 3B). Ex4-
induced cardioprotection was not affected by bilateral cervical vagot-
omy (infarct size 276 11%, NS vs. Ex4 treatment) (Figure 3B).
However, systemic muscarinic receptor blockade (atropine) abol-
ished Ex4-induced cardioprotection (infarct size 526 9%, P< 0.01 vs.
Ex4). Ex4 also failed to establish cardioprotection in conditions of
systemic M3 receptor blockade with 4-DAMP (infarct size 576 6%,
P< 0.001 vs. Ex4) (Figure 3B).
3.4 Experiment 4. The effect of RIc on
plasma level of GLP-1
Moderate increases in the level of circulating (arterial) GLP-1 compared
to the baseline values were observed 30min after the onset of limbs
ischaemia (15min into the limb reperfusion period) (4.76 0.9 vs.
3.06 0.7 pg/ml at baseline; P< 0.05; Table 1). Arterial GLP-1 levels were
not affected by sham-RIc procedure (Table 1).
4. Discussion
To the best of our knowledge, this is the first experimental study which
demonstrated that a particular humoral factor is causally involved in car-
dioprotection induced by remote ischaemic conditioning. Recent study
identified the likely origin of the cardioprotective humoral factor which
appears to be produced by the visceral organs innervated by the poste-
rior gastric branch of the vagus nerve.21 Organs of the gastrointestinal
tract indeed represent a major source of many factors with known cardi-
oprotective properties, including GLP-1. Here we show that the remote
conditioning-induced cardioprotection and phosphorylation of pro-
survival kinase AKT are abolished by systemic GLP-1R blockade with
Ex(9–39). Ex(9–39) has been used in many published studies, including
several seminal reports, which described physiological role and signifi-
cance of GLP-1R-mediated signalling,40 and off-target (i.e. not on GLP-
Figure 3 Cardioprotection induced by GLP-1 receptor activation is
mediated by a muscarinic mechanism. (A) Illustration of the experimen-
tal protocols. Downward arrows indicate time (15min before myocar-
dial ischaemia) of intravenous administration of GLP-1 receptor agonist
Exendin-4 (Ex4). Upward arrows indicate time (30min before myocar-
dial ischaemia) of cervical vagotomy, start of atropine infusion or admin-
istration of M3 muscarinic receptor antagonist 4DAMP. (B) Infarct size
is presented as a percentage of the area at risk. Individual data and
means6 SD are shown. **P< 0.01; ***P< 0.001.
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.1R) effects of this peptide antagonist have never been observed. The
data obtained also suggest that pathways of cardioprotection down-
stream of GLP-1R activation are independent of vagal activity but involve
recruitment of M3 receptor-dependent mechanism. These results are in
agreement with the data reported recently, showing that in isolated
hearts cardioprotection established by plasma dialysate collected from
rats receiving the RIc stimulus is abolished by muscarinic receptor
blockade.41
4.2 Vagus nerve and remote ischaemic
conditioning cardioprotection
Since the importance of vagal mechanisms in mediating cardioprotection
induced by RIc was first proposed,42 results of several experimental
studies provided strong evidence in support of the idea that the intact
parasympathetic mechanisms are essential for RIc cardioprotection.
RIPre cardioprotection was found to be abolished by selective genetic
targeting and silencing of vagal preganglionic neurones, bilateral cervical
vagotomy or systemic muscarinic receptor blockade.3,13,14 Anatomical
and functional cholinergic innervation of the cardiac ventricles was dem-
onstrated in a number of studies (for recent experimental reports see
Refs43,44) and it was suggested that RIPre is mediated by the actions of
acetylcholine released from vagal efferent fibres which innervate the LV
myocardium.13 However, the mechanism involving vagally-mediated
reflexes cannot fully explain how RIPre is able to protect the trans-
planted or denervated hearts, or cross species transfer of RIc cardiopro-
tection by plasma dialysate.8–11 Taken together, the available data
suggest that production and release of a humoral factor of RIc cardiopro-
tection is under parasympathetic control. In support of this idea, it was
recently demonstrated that RIPre fails to establish cardioprotection in
conditions of selective sectioning of the posterior gastric branch of the
vagus nerve,21 pointing to the likely source of the cardioprotective
humoral factor. Results of the present study show that RIPer cardiopro-
tection also requires intact parasympathetic innervation of visceral
organs. Therefore, the common vagal mechanisms appear to mediate
cardioprotection established by RIc applied either before or during myo-
cardial ischaemia and require GLP-1R-mediated signalling.
4.3 Humoral factor(s) of RIc
cardioprotection. The role of
GLP-1R-mediated signalling
A significant number of studies demonstrated successful transfer of
humoral factor responsible for RIc cardioprotection with plasma or dial-
ysate, obtained after RIc, to another animal or isolated hearts, even
across species (see for example Refs8,10,11,41) The molecular weight of
this humoral factor of cardioprotection appears to be less than 8 kDa,34
and several candidate molecules have been proposed.15–19 Cell-derived
factor-1a,15 nitrite/nitric oxide,16 interleukin-10,17 microRNA-14418
were shown to be involved in cardioprotection; however, RIc cardiopro-
tection cannot be fully explained by any of the identified factors acting
alone. In addition, SDF-1a has been proposed to act as a circulating
mediator of RIc.15 However, treatment with a selective inhibitor of SDF-
1a only partially attenuated but did not block RIc cardioprotection,15
suggesting the existence of other (parallel) mechanisms. Proteome/
sequencing analysis also failed to reveal the nature of this factor.34,45,46
One recent study reported RIc-induced changes in plasma levels of
seven proteins.46 These factors are involved in the control of haemosta-
sis, lipid transport, iron regulation and inflammation. Some of the identi-
fied proteins (when applied exogenously) could mimic RIc in
experimental models; however, it remains unknown whether blockade
of their actions has an effect on RIc cardioprotection.
GLP-1 can activate GLP-1R expressed by visceral vagal afferents acting
in a paracrine manner, but also has endocrine functions.24,25 Originally
identified to be expressed by pancreatic b-cells, GLP-1R is now known
to be widely distributed in many tissues, including the atrial myocardium,
coronary vessels, and possibly, ventricles.47 Several studies demon-
strated high efficacy of GLP-1R agonists in reducing the infarct size.30
However, the mechanisms by which GLP-1R activation protects the
ischaemic myocardium remain largely unknown. Both GLP-1R-
dependent and GLP-1R-independent mechanisms have been pro-
posed.28,29 As the majority of the intestinally derived GLP-1 is degraded
by the DPP-4, low levels of circulating GLP-1 are usually reported.24
Due to high rate of enzymatic degradation and renal clearance, GLP-1
has a short half-life (1–2min) in plasma which represents a major limita-
tion for its detection.24,48 In this study, we observed moderate increases
in plasmaGLP-1 level 30min after the onset of the RIc stimulus, probably
due to high variability of GLP-1 plasma concentration and short half-life
of GLP-1. Interestingly, the long-lasting beneficial effects of short-term
GLP-1 infusion have been shown to persist for weeks even when the cir-
culating levels of GLP-1 return back to normal levels.49
The central finding of the present study is that highly selective GLP-1R
antagonist Ex(9–39) administered before RIPre or RIPer blocks cardio-
protection induced by both RIc stimuli. GLP-1R blockade also prevented
the stimulatory effect of RIPre on AKT phosphorylation. It appears that
different animal species recruit distinct cardioprotective signalling path-
ways. In rodents, RISK pathway (AKT) activation is essential to establish
cardioprotection,50 but SAFE pathway (STAT3) also plays a role.51 In
mice and rats, robust activation of RISK and SAFE pathways is observed
in isolated hearts and in vivo preparations following application of various
conditioning stimuli (RIPre and remote postconditioning) as well as phar-
macologically.11,50,52–56 Importantly, there is also evidence that both RIc
cardioprotection52 and cardioprotection induced by activation of GLP-
...................................................................................................................................................................
..............................................................................................................................................................................................................................
Table 1 The effect of remote ischaemic conditioning (RIc) or sham-RIc on plasma level of glucagon-like peptide-1
(in pg ml 1)
Time from the onset of limb ischaemia or sham (min)
n 210 5 20 30
Sham 8 4.16 0.7 5.26 1.0 4.46 0.9 5.16 1.1
RIc 8 3.06 0.7 3.16 0.6 3.46 0.6 4.76 0.9*
*Significant difference from the baseline value (P< 0.05).
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..1R57 are abolished in conditions of AKT blockade. In rodents, inhibition
of either RISK or SAFE pathway blocks cardioprotection11,52,54,56 sug-
gesting that the elements of these two protective pathways may interact.
In pigs and humans, cardioprotection appears to be predominantly asso-
ciated with activation of SAFE pathway.58,59 The data obtained in this
study suggest that (at least in rats) GLP-1R-mediated signalling is essential
for RIc cardioprotection by being responsible for triggering activation of
the pro-survival RISK pathway and, therefore, GLP-1 is likely to act as
the key humoral factor of this phenomenon.
4.4 The significance of cardiac vagal
mechanisms in cardioprotection induced
by GLP-1R activation
Potent cardioprotective effects of GLP-1R agonists have been dem-
onstrated previously.30 However, the underlying mechanisms of
GLP-1R-mediated cardioprotection remained largely unknown. Data
showing that only atrial cardiomyocytes express GLP-1R,47 together
with the evidence that GLP-1R agonists can establish cardioprotec-
tion in conditions of selective genetic GLP-1R deletion in ventricular
cardiomyocytes,29 highlight major gaps in our understanding of GLP-
1-induced cardioprotection. Here we addressed the potential mecha-
nisms using systemic administration of a stable GLP-1R agonist Ex4,
which is not readily cleaved by DPP-4. Cardioprotection established
by Ex4 was found to be abolished in conditions of systemic muscar-
inic receptor blockade with atropine and, more specifically, M3
receptor blockade with 4-DAMP, whereas vagotomy had no effect.
These data suggest that (most likely) cardiac M3-receptor mediated
mechanisms are crucial for cardioprotection induced by Ex4. The
hypothesised functions of cardiac M3 receptors include regulation of
heart rate and cardiac repolarization, modulation of inotropic effects,
regulation of cell-to-cell communication, and protection from ischae-
mia/reperfusion injury.60 We suggest that GLP-1 activates GLP-1R
expressed by vagal efferent fibres innervating the ventricles, triggering
pre-junctional release of acetylcholine, which protects ventricular
cardiomyocytes via activation of M3 muscarinic receptors. Although,
testing this hypothesis is beyond the scope of the present study, it is
strongly supported by the recent data obtained by Pickard and col-
leagues showing that in isolated rat hearts, cardioprotection estab-
lished by plasma dialysate from donor rats receiving RIc stimulus is
abolished by muscarinic receptor blockade.41
4.5 Translational perspective
Results of several clinical studies demonstrated the efficacy of RIc in
reducing infarct size in patients with AMI4,5 as well as improvement of
long term prognosis in these patients.6 Other clinical reports demon-
strated lack of RIc effect in patients undergoing cardiac surgery.61 In con-
trast, clinical studies which tested the efficacy of GLP-1R agonists in
establishing cardioprotection demonstrated significant reductions in
infarct size, regardless of comorbidities and prescribed medications.31,32
Results of the present study demonstrate that RIc cardioprotection is
dependent on the actions of GLP-1, while cardioprotection induced by
GLP-1R activation is independent of parasympathetic mechanisms but is
mediated via M3 muscarinic receptor activation. These results provide a
strong rationale for combination of RIc and intravenous GLP-1R agonists
in patients with AMI.
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